Integra LifeSciences Holdings (IART)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	67,741	100,853	131,271	171,875	180,550	172,988	166,302	156,582	169,075	216,435	205,543	170,106	133,892	56,467	-3,480	26,625	50,201	60,020	100,925	82,565
Total assets	US$ in thousands	3,781,990	3,739,370	3,777,600	3,742,400	3,889,760	3,807,010	3,752,860	3,672,000	3,782,380	3,774,460	3,712,790	3,741,550	3,615,140	3,453,520	3,391,760	3,447,560	3,303,240	3,346,580	3,290,410	3,205,710
ROA		1.79%	2.70%	3.47%	4.59%	4.64%	4.54%	4.43%	4.26%	4.47%	5.73%	5.54%	4.55%	3.70%	1.64%	-0.10%	0.77%	1.52%	1.79%	3.07%	2.58%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $67,741K ÷ $3,781,990K
= 1.79%

Integra Lifesciences Holdings Corp's return on assets (ROA) has exhibited a declining trend over the past eight quarters, decreasing from 4.64% in Q4 2022 to 1.79% in Q4 2023. This indicates that the company's ability to generate profits relative to its total assets has weakened. It is worth noting that the ROA had shown a consistent improvement from Q1 2022 to Q1 2023, reaching a peak of 4.59% in Q1 2023 before declining in subsequent quarters.

A declining ROA could be a cause for concern as it suggests that the company may be less efficient in utilizing its assets to generate earnings. Management may need to closely monitor and assess the factors contributing to this downward trend in order to optimize asset utilization and improve overall profitability.